NCT02531906View on ClinicalTrials.gov

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 24, 2015

Primary Completion Date

June 14, 2018

Study Completion Date

June 14, 2018

Conditions

Head and Neck Squamous Cell CarcinomaPainStomatitis

Interventions

DRUG

Gabapentin

Given PO

DRUG

Methadone Hydrochloride

Given PO

DRUG

Oxycodone Hydrochloride

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER

NCT02531906 - Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation | Biotech Hunter | Biotech Hunter